Clarithromycin (Klaromin 500 mg) and Tofacitinib: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Systemic strong CYP3A4 inhibition can increase tofacitinib exposure.
Clinical significance and safety
Klaromin 500 mg contains a systemic strong CYP3A4 inhibitor and can increase tofacitinib exposure and adverse-effect risk. The tofacitinib label recommends a prescriber-directed modification when used with strong CYP3A4 inhibitors. Confirm the full regimen with the prescriber or pharmacist before coadministration.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.